StockData

Biomerica vs Dyadic International

BMRA and DYAI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BMRA and DYAI compare

Dyadic International is the larger company, worth 1.9 times as much as Biomerica ($11.7M against $6.1M).

Dyadic International grew revenue faster over the last twelve months (−7.6% versus −11.2% for Biomerica).

Biomerica keeps more of each dollar of sales as profit, with a net margin of −115% compared with −227% at Dyadic International.

Biomerica scores higher on the StockData Score (8 against 7 for Dyadic International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBMRADYAI
Size and price
Market cap$6.1M$11.7M
Share price$1.32$0.320
Change, 1 year−47.2%−64.6%
Change, 5 years−96.7%−91.4%
Beta (5Y)0.841.44
Employees175
StockData Score
Total score8 (better)7
Valuation score3 (better)1
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S1.4× (better)3.8×
P/B1.7×–
Fair value$2.49–
Margin of safety47.0%–
Growth
Revenue growth (TTM)−11.2%−7.6% (better)
Revenue growth, 5Y average−9.2%14.0% (better)
Profitability
Gross margin0.90%17.9% (better)
Operating margin−125% (better)−237%
Net margin−115% (better)−227%
Return on equity−114% (better)−47256%
Return on invested capital−284%–
Financial health
Debt / equity0.00–
Current ratio1.91 (better)1.69
Altman Z-score−10.57 (better)−18.95
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−52.2%–
Shareholder yield−52.2%0.00% (better)
Ownership
Held by institutions2.7%12.7%
Held by insiders27.4%28.0%
Insider net buying, 12 months$158K (better)−$125K
Short interest, % of float0.37%0.32%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.